NCT06415851View on ClinicalTrials.gov

Chemotherapy Plus Bevacizumab and Anti-PD-1 Followed by Induction Therapy of Chemotherapy Plus Bevacizumab

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

May 30, 2025

Study Completion Date

May 30, 2026

Conditions
Metastatic Colorectal CancerMSS
Interventions
DRUG

mFOLFOX6 regimen + bevacizumab + PD-1 monoclonal antibody

This study is a single-arm intervention study. All subjects in this study will be treated with this study protocol, that is, after mFOLFOX6 protocol and bevacizumab induction therapy, combined with slulimumab treatment.

Trial Locations (1)

310012

Sir Run Run Shao hospital, Hanzhou

All Listed Sponsors
lead

Zhangfa Song

OTHER

NCT06415851 - Chemotherapy Plus Bevacizumab and Anti-PD-1 Followed by Induction Therapy of Chemotherapy Plus Bevacizumab | Biotech Hunter | Biotech Hunter